Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) are currently up by more than -25.83% from the open today and are trading at $7.90. More than 525,155 shares have exchanged hands compared to an average trading volume of 624.60K. At the current pps, the market cap stands at $121.79M. The stock prices of Catalyst Biosciences, Inc. (NASDAQ:CBIO) are currently trading at -27.86% below its 52 week high and 1655.40% above its 52 week low.
Catalyst Biosciences, Inc. (NASDAQ:CBIO) has been in the news for all the right reasons. Recently, Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced an update on its clinical development plans for its next-generation Factor VIIa and Factor IX candidates and reiterated its intention to commence two clinical trials in individuals with hemophilia B in 2017.
The Company plans to initiate a subcutaneous (SQ) efficacy trial of marzeptacog alfa (activated), a next-generation Factor VIIa, in individuals with hemophilia B with inhibitors in 2017. In addition, Catalyst and its collaboration partner, ISU Abxis, plan to initiate a SQ Phase 1/2 proof-of-concept clinical trial of CB 2679d/ISU304, a next-generation coagulation Factor IX, in individuals with hemophilia B in the second quarter of 2017.
Nassim Usman, Ph.D., President and Chief Executive Officer, presented at the 19th Annual BIO CEO & Investor Conference held in New York City. A copy of Dr. Usman’s presentation slides can be found in the Investors section of the Company’s website. Read Mo
Catalyst Biosciences, Inc. (NASDAQ:CBIO) is all set to announce its earnings on Feb 23/a. As per Zack’s analyst ratings, Catalyst Biosciences, Inc. (NASDAQ:CBIO) currently has an average brokerage rating of 1. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:CBIO) is $2 with a high of $2 and a low of $2.
Let’s take a look at the technical analysis.The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The 5 day EMA 8.18 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 9.65 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 43.52 suggesting a bearish price action.
Wall Street PR - Winning in 2017!http://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
2017 Most Disruptive Biotech IMLFFhttp://www.financialstrend.com
Disruptive biotech IMLFF decodes targeted drug delivery for stem cells
Enter The $100 Billion Gaming Markethttp://www.financialstrend.com
Gaming industry setup for explosive growth
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.financialstrend.com/disclaimer